Expression of p63 in diffuse large B-cell lymphoma

Applied Immunohistochemistry and Molecular Morphology

Volumn 13, Issue 3, 2005, Pages 237-242

  Hedvat, Cyrus V ^a   Teruya Feldstein, Julie ^a   Puig, Pere ^a   Capodieci, Paola ^a   Dudas, Maria ^a   Pica, Natalie ^a   Qin, Jing ^a   Cordon Cardo, Carlos ^a   Di Como, Charles J ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b Aureon Biosciences   (United States)

Author keywords

Lymphoma; p63; Tissue microarray

Indexed keywords

GENE PRODUCT; ISOPROTEIN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 4A4; PROTEIN P63; UNCLASSIFIED DRUG;

ARTICLE; B CELL LYMPHOMA; CARCINOGENESIS; CELL PROLIFERATION; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; EPITHELIUM; GENE AMPLIFICATION; GENE EXPRESSION; GERMINAL CENTER; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; MAJOR CLINICAL STUDY; P63 GENE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TUMOR CELL LINE; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

ANALYSIS OF VARIANCE; CELL LINE, TUMOR; CELL PROLIFERATION; COHORT STUDIES; DISEASE PROGRESSION; DNA-BINDING PROTEINS; GENES, TUMOR SUPPRESSOR; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES; LYMPHOMA, B-CELL; LYMPHOMA, LARGE-CELL, DIFFUSE; PHOSPHOPROTEINS; PROTEIN ISOFORMS; SURVIVAL ANALYSIS; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEINS;

EID: 23944512761     PISSN: 15412016     EISSN: 15334058     Source Type: Journal    
DOI: 10.1097/01.pai.0000142160.52670.ce     Document Type: Article

References (36)

1. Yang A, McKeon F. P63 and P73: P53 mimics, menaces and more. Nat Rev Mol Cell Biol. 2000;1:199-207.
2. Yang A, Kaghad M, Wang Y, et al. p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. Mol Cell. 1998;2:305-316.
3. Di Como CJ, Urist MJ, Babayan I, et al. p63 expression profiles in human normal and tumor tissues. Clin Cancer Res. 2002;8:494-501.
4. Hall PA, Campbell SJ, O'Neill M, et al. Expression of the p53 homologue p63alpha and deltaNp63alpha in normal and neoplastic cells. Carcinogenesis. 2000;21:153-160.
5. Nylander K, Vojtesek B, Nenutil R, et al. Differential expression of p63 isoforms in normal tissues and neoplastic cells. J Partial. 2002;198:417-427.
6. Yang A, Schweitzer R, Sun D, et al. p63 is essential for regenerative proliferation in limb, craniofacial and epithelial development. Nature. 1999;398:714-718.
7. Mills AA, Zheng B, Wang XJ, et al. p63 is a p53 homologue required for limb and epidermal morphogenesis. Nature. 1999;398:708-713.
8. Signoretti S, Waltregny D, Dilks J, et al. p63 is a prostate basal cell marker and is required for prostate development. Am J Pathol. 2000;157:1769-1775.
9. Parsa R, Yang A, McKeon F, et al. Association of p63 with proliferative potential in normal and neoplastic human keratinocytes. J Invest Dermatol. 1999;113:1099-1105.
10. Hibi K, Trink B, Patturajan M, et al. AIS is an oncogene amplified in squamous cell carcinoma. Proc Natl Acad Sci USA. 2000;97:5462-5467.
11. Crook T, Nicholls JM, Brooks L, et al. High level expression of deltaN-p63: a mechanism for the inactivation of p53 in undifferentiated nasopharyngeal carcinoma (NPC). Oncogene. 2000;19:3439-3444.
12. Yamaguchi K, Wu L, Caballero OL, et al. Frequent gain of the p40/p51/p63 gene locus in primary head and neck squamous cell carcinoma. Int J Cancer. 2000;86:684-689.
13. Massion PP, Taflan PM, Jamshedur Rahman SM, et al. Significance of p63 amplification and overexpression in lung cancer development and prognosis. Cancer Res. 2003;63:7113-7121.
14. Urist MJ, Di Como CJ, Lu M, et al. Loss of p63 expression is associated with tumor progression in bladder cancer. Am J Pathol. 2002;161:1199-1206.
15. Yamaguchi H, Inokuchi K, Sakuma Y, et al. Mutation of the p51/p63 gene is associated with blastic crisis in chronic myelogenous leukemia. Leukemia. 2001;15:1729-1734.
16. Chiarle R, Budel LM, Skolnik J, et al. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma. Blood. 2000;95:619-626.
17. Chang CC, Liu YC, Cleveland RP, et al. Expression of c-Myc and p53 correlates with clinical outcome in diffuse large B-cell lymphomas. Am J Clin Pathol. 2000;113:512-518.
18. Sander CA, Yano T, Clark HM, et al. p53 mutation is associated with progression in follicular lymphomas. Blood. 1993;82:1994-2004.
19. Harris NL, Jaffe ES, Diebold J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November 1997. J Clin Oncol. 1999;17:3835-3849.
20. Hoos A, Cordon-Cardo C. Tissue microarray profiling of cancer specimens and cell lines: opportunities and limitations. Lab Invest. 2001;81:1331-1338.
21. Kononen J, Bubendorf L, Kallioniemi A, et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med. 1998;4:844-847.
22. Hoos A, Urist MJ, Stojadinovic A, et al. Validation of tissue microarrays for immunohistochemical profiling of cancer specimens using the example of human fibroblastic tumors. Am J Pathol. 2001;158:1245-1251.
23. Di Como CJ, Gaiddon C, Prives C. p73 function is inhibited by tumor-derived p53 mutants in mammalian cells. Mol Cell Biol. 1999;19:1438-1449.
24. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1957;53:457-481.
25. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemo Report. 1966;50:163-170.
26. Michael D, Oren M. The p53 and Mdm2 families in cancer. Curr Opin Genet Dev. 2002;12:53-59.
27. Louie DC, Offit K, Jaslow R, et al. p53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32). Blood. 1995;86:2892-2899.
28. Novak U, Grob TJ, Baskaynak G, et al. Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. Ann Oncol. 2001;12:981-986.
29. Com PG, Kuerbitz SJ, van Noesel MM, et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res. 1999;59:3352-3356.
30. Senoo M, Tsuchiya I, Matsumura Y, et al. Transcriptional dysregulation of the p73L/p63/p51/p40/KET gene in human squamous cell carcinomas: expression of delta Np73L, a novel dominant-negative isoform, and loss of expression of the potential tumour suppressor p51. Br J Cancer. 2001;84:1235-1241.
31. Chaganti SR, Chen W, Parsa N, et al. Involvement of BCL6 in chromosomal aberrations affecting band 3q27 in B-cell non-Hodgkin lymphoma. Genes Chromosomes Cancer. 1998;23:323-327.
32. Offit K, Louie DC, Parsa NZ, et al. BCL6 gene rearrangement and other cytogenetic abnormalities in diffuse large cell lymphoma. Leuk Lymphoma. 1995;20:85-89.
33. Ogutcen-Toller M, Gulen O, Okten G, et al. Non-Hodgkin's lymphoma in a patient with ectrodactyly ectodermal dysplasia-clefting syndrome. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90:124-125.
34. Gershoni-Baruch R, Goldscher D, Hochberg Z. Ectrodactyly-ectodermal dysplasia-clefting syndrome and hypothalamo-pituitary insufficiency. Am J Med Genet. 1997;68:168-172.
35. Akahoshi K, Sakazume S, Kosaki K, et al. EEC syndrome type 3 with a heterozygous germline mutation in the P63 gene and B cell lymphoma. Am J Med Genet. 2003;120A:370-373.
36. The role of p63 and p73 in tumor formation and progression: coming of age toward clinical usefulness. Clin Cancer Res. 2003;9:5437-5441.